Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
A plain language summary of what clinical studies can tell us about the safety of evobrutinib - a potential treatment for multiple sclerosis.
Journal: Neurodegenerative disease management
Published: June 22, 2023
Enpatoran in COVID-19 pneumonia: Safety and efficacy results from a phase II randomized trial.
Journal: Clinical and translational science
Published: March 15, 2023
Identifying lupus Patient Subsets Through Immune Cell Deconvolution of Gene Expression Data in Two Atacicept Phase II Studies.
Journal: ACR open rheumatology
Published: December 22, 2022
Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient-level placebo (Standard-of-Care) data to enable model-informed drug development.
Journal: CPT: pharmacometrics & systems pharmacology
Published: August 01, 2022
Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial.
Journal: ACR open rheumatology
Published: July 14, 2022
Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria.
Journal: Kidney international reports
Published: March 04, 2022
Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: January 05, 2022
Disease course following High Disease Activity Status revealed patterns in SLE.
Journal: Arthritis research & therapy
Published: May 04, 2021
Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus.
Journal: Rheumatology (Oxford, England)
Published: November 03, 2020
Algorithm for calculating high disease activity in SLE.
Journal: Rheumatology (Oxford, England)
Published: October 12, 2020
The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research.
Journal: Lupus science & medicine
Published: August 10, 2020
Commentary: Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders.
Journal: Frontiers in immunology
Published: August 07, 2020
Last Updated: 09/26/2026